Efficacy of a bleomycin microneedle patch for the treatment of warts
- 523 Downloads
Warts are a common skin disease caused by infection of the human papilloma virus. Most treatments involving physical destruction of the infected cells, such as cryotherapy and electrocautery, are limited by intense pain, failure, or recurrences. Our aim was to compare the therapeutic effects of a newly developed bleomycin microneedle patch with cryotherapy in the treatment of warts. Forty-two patients with more than two wart lesions were included in the study. The two treatment modalities were randomly applied to different warts on each patient. Treatment efficacy was assessed using the Physician’s Global Assessment (PGA) and the Patient’s Global Assessment (PaGA). Mean PGA and PaGA scores were not significantly different between cryotherapy and bleomycin microneedle patch treatment. It was also determined that the mean size of all the warts treated with either modality shrank about equally at weeks 8 and 16 after initial treatment. Thus, treatment efficacy of the bleomycin microneedle patch was comparable to that of conventional cryotherapy. According to a visual analogue scale of pain, bleomycin microneedle patch treatment was significantly less painful than cryotherapy (p < .0001). In addition, use of the bleomycin microneedle patch was more tolerable for patients who were reluctant to receive the painful treatment. Thus, the bleomycin microneedle patch can be an effective, convenient, and innovative treatment modality for warts.
KeywordsBleomycin microneedle patch Cryotherapy Treatment of warts Pain Efficacy
This research was supported by the Gachon University Gil Medical Center (Grant number: 2013-47), a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, and by the Technology Innovation Program (10067809, Development of vaccine formulation and patient-convenient vaccine microneedle) funded by the Ministry of Trade, Industry & Energy (MOTIE, Korea).
Compliance with ethical standards
The study protocol was approved by the institutional review board (GDIRB2013-16) of Gil Medical Center and conformed to the principles outlined in the Declaration of Helsinki. Written informed consent was obtained from all subjects before they were enrolled in the study.
Conflict of interest
Authors declare that they have no conflict of interest.
- 2.Willian TGB James D, Dirk M. Elston, Andrew’s diseases of the skin: clinical dermatology. 2011.Google Scholar
- 3.Lee JR, Youn JH, Roh JY. Intralesional vincristine combined with cryotherapy for recalcitrant verrucas. Dermatol Ther. 2011;24(3):380–3. https://doi.org/10.1111/j.1529-8019.2011.01425.x.
- 4.Berth-Jones J, Bourke J, Eglitis H, Harper C, Kirk P, Pavord S, et al. Value of a second freeze-thaw cycle in cryotherapy of common warts. Br J Dermatol. 1994;131(6):883–6. https://doi.org/10.1111/j.1365-2133.1994.tb08594.x.
- 8.Shelley WB, Shelley ED. Intralesional bleomycin sulfate therapy for warts. A novel bifurcated needle puncture technique. Arch Dermatol. 1991;127(2):234–6. https://doi.org/10.1001/archderm.1991.01680020102014.CrossRefPubMedGoogle Scholar
- 9.Bunney MH, Nolan MW, Buxton PK, Going SM, Prescott RJ. The treatment of resistant warts with intralesional bleomycin: a controlled clinical trial. Br J Dermatol. 1984;111(2):197–207. https://doi.org/10.1111/j.1365-2133.1984.tb04044.x.CrossRefPubMedGoogle Scholar
- 12.Munn SE, Higgins E, Marshall M, Clement M. A new method of intralesional bleomycin therapy in the treatment of recalcitrant warts. Br J Dermatol. 1996;135(6):969–71. https://doi.org/10.1046/j.1365-2133.1996.d01-1104.x.CrossRefPubMedGoogle Scholar
- 15.Miller RA. Nail dystrophy following intralesional injections of bleomycin for a periungual wart. Arch Dermatol. 1984;120(7):963–4. https://doi.org/10.1001/archderm.1984.01650430153030.CrossRefPubMedGoogle Scholar
- 16.Urbina Gonzalez F, Cristobal Gil MC, Aguilar Martinez A, Guerra Rodriguez P, Sanchez de Paz F, Garcia-Perez A. Cutaneous toxicity of intralesional bleomycin administration in the treatment of periungual warts. Arch Dermatol. 1986;122(9):974–5. https://doi.org/10.1001/archderm.122.9.974.CrossRefPubMedGoogle Scholar
- 20.Rebecca EL, Lutton EM, Woolfson D, Donnelly RF. Microneedle arrays as transdermal and intradermal drug delivery systems: materials science, manufacture and commercial development. Mater Sci Eng: R: Rep. 2017;104:1–32.Google Scholar
- 22.Zhao X, Coulman SA, Hanna SJ, Wong FS, Dayan CM, Birchall JC. Formulation of hydrophobic peptides for skin delivery via coated microneedles. J Cotrol Rel. 2017;In-press.Google Scholar
- 24.Takigawa M, Oku T, Ginoza M, Yamada M, Yamamoto T, Kobayashi I. Treatment of viral warts with pressure-sensitive adhesive tape containing bleomycin sulfate. Arch Dermatol. 1985;121(9):1108. https://doi.org/10.1001/archderm.1985.01660090022008.CrossRefPubMedGoogle Scholar
- 27.C.W.K Won Ho Kim, Kwang Ho Kim, Kwang Joong Kim. Intralesional bleomycin therapy using a lancet in the treatment of recalcitrant warts. Ann Dermatol. 2005;17:53–57.Google Scholar
- 28.Kruter L, Saggar V, Akhavan A, Patel P, Umanoff N, Viola KV, et al. Intralesional bleomycin for warts: patient satisfaction and treatment outcomes. J Cutan Med Surg. 2015;19(5):470–6. https://doi.org/10.1177/1203475415576860.